Discusses the potential of nuclear medicine and magnetic resonance imaging to quantitatively measure in vivo pathology of myocardial infarction.
May guide imaging biomarker development in MI; leaves open prospective validation before clinical adoption.
In order to measure the effectiveness of new therapies a technique is needed which can measure quantitatively in vivo pathology. In cardiology, the introduction of thrombolytic agents, which lyse the initial thrombus, has given added stimulus to the search for techniques which would fill this role. In this paper the extent to which nuclear medicine and magnetic resonance imaging can meet the requirements is discussed.
No takes yet. Share an insight, caveat, or question.
Alexander Muir (1990) studied this question.